Agios Pharmaceuticals, Inc. (8AP.F)
Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
As of 08:03AM CEST. Market open.
| Previous Close | 30.20 |
| Open | 30.60 |
| Bid | 30.20 x 20000 |
| Ask | 31.00 x 20000 |
| Day's Range | 30.60 - 30.60 |
| 52 Week Range | 18.80 - 32.20 |
| Volume | |
| Avg. Volume | 10 |
| Market Cap | 1.761B |
| Beta (5Y Monthly) | 0.81 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks
Wall Street Analysts See a 26.01% Upside in Agios Pharmaceuticals (AGIO): Can the Stock Really Move This High?
The consensus price target hints at a 26% upside potential for Agios Pharmaceuticals (AGIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- Simply Wall St.
Earnings Beat: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Investors in Agios Pharmaceuticals, Inc. ( NASDAQ:AGIO ) had a good week, as its shares rose 9.7% to close at US$34.54...
- Zacks
Agios (AGIO) Q1 Earnings Surpass, Sales Miss Estimates
Agios (AGIO) reports mixed earnings results for first-quarter 2024. Though sales miss the mark, revenues from its sole marketed drug, Pyrukynd, rise sequentially and on a yearly basis.
© 2024 Yahoo. All rights reserved.